Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?

References

• Michallet AS, Coiffier B. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 2009;23:11–23.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–33.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21–6.
   PubMed Web of Science ®Google Scholar
• Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007;25:787–92.
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197–204.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, et al. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010;8:288–334.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352: 1197–205.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032–8.
   PubMed Web of Science ®Google Scholar
• Miller T, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001;98:724a.
   Google Scholar
• Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26: 2258–63.
   PubMed Web of Science ®Google Scholar
• Mian M, Marcheselli L, Rossi A, Visco C, Chiappella A, Volpetti S, et al. A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. Ann Oncol 2014;25:2398–404.
   PubMed Web of Science ®Google Scholar
• Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol 2013;31:4115–22.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Klasa R, Shenkier T, et al. Long-term experience with PET-guided consolidation radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol 2013;31:96–150.
   PubMedGoogle Scholar
• Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, et al. Combined modality treatment for PET-positive non-Hodgkin lymphoma: Favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys 2012;83:e647–54.
   Google Scholar
• Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, et al. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high risk limited stage aggressive B-cell lymphoma: SWOG S0313. Blood 2014; 8;125: 236–41.
   Web of Science ®Google Scholar
• Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Henvrecht R, Bossy A, et al. Prognostic factors in aggressive malignant lymphoma. Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991;9:211–9.
   Google Scholar
• Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, et al. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 2012;84:762–7.
   PubMed Web of Science ®Google Scholar
• Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys 2013;86:569–77.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435–44.
   PubMed Web of Science ®Google Scholar
• Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 2014;32:1112–8.
   PubMed Web of Science ®Google Scholar
• Avilés A, Neri N, Delgado S, Pérez F, Nambo MJ, Cleto S, et al. Residual disease after chemotherapy in aggressive malignant lymphoma: The role of radiotherapy. Med Oncol 2005;22:383–7.
   PubMed Web of Science ®Google Scholar
• Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170–6.
   PubMedGoogle Scholar
• Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or with- out etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–41.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012;13:1250–9.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013–22.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymph 2010;51:1225–32.
   PubMed Web of Science ®Google Scholar